Vimpat/Vimpat Injection

Vimpat/Vimpat Injection

lacosamide

Manufacturer:

Abbott

Distributor:

Abbott
Concise Prescribing Info
Contents
Lacosamide
Indications/Uses
Monotherapy & adjunctive therapy in partial-onset seizures w/ or w/o secondary generalisation in patients ≥16 yr w/ epilepsy.
Dosage/Direction for Use
Monotherapy Initially 100 mg bid, increased to 150 mg bid after 1 wk. May be further increased at wkly interval by 50 mg bid (100 mg daily) depending on response & tolerability. Max maintenance dose: 200 mg bid (400 mg daily). Conversion to monotherapy Initially 100 mg bid, increased to 150 mg bid after 1 wk. May be further increased at wkly interval by 50 mg bid (100 mg daily). Max maintenance dose: 200 mg bid (400 mg daily). Adjunctive therapy Initially 50 mg bid, increased to initial therapeutic dose of 100 mg bid after 1 wk. May be further increased by 50 mg bid (100 mg daily) every wk. Max maintenance dose: 200 mg bid (400 mg daily). Initiation w/ loading dose Initiate w/ single loading dose of 200 mg, followed approx 12 hr later by 100 mg bid (200 mg daily) maintenance dose. Can be further increased by 50 mg bid wkly. Max maintenance dose: 200 mg bid (400 mg daily). Severe renal impairment (CrCl ≤30 mL/min) & ESRD, mild to moderate hepatic impairment Max: 300 mg daily. Patient requiring haemodialysis Supplement of up to 50% of divided daily dose directly after end of haemodialysis.
Administration
May be taken with or without food: Do not divide tab.
Special Precautions
Dizziness; prolongation in PR interval, 2nd-degree or higher AV block. Patients w/ cardiac conduction problems or severe cardiac disease eg, myocardial ischaemia/infarction, heart failure, structural heart disease or cardiac Na channelopathies. Monitor for signs of suicidal ideation & behaviours. Concomitant use w/ medicinal products affecting cardiac conduction including antiarrhythmics & Na channel blocking antiepileptics. Patient w/ phenylketonuria. ESRD. Severe hepatic impairment. May have minor to moderate influence on ability to drive & use machines. Not to be used during pregnancy. Lactation. Not recommended in childn & adolescents <16 yr. Elderly.
Adverse Reactions
Dizziness, headache; diplopia; nausea. Depression, confusional state, insomnia; cognitive & balance disorder, nystagmus, memory impairment, tremor, somnolence, dysarthria, attention disturbance, hypoesthesia, paraesthesia; blurred vision; vertigo, tinnitus; vomiting, constipation, flatulence, dyspepsia, dry mouth, diarrhea; pruritus; muscle spasms; gait disturbance, asthenia, fatigue, irritability, feeling drunk; fall, skin laceration; contusion.
Drug Interactions
Concomitant use w/ medicinal products associated w/ PR prolongation (eg, Na channel blocking antiepileptics) & antiarrhythmics. Potential to inhibit CYP2C19 at therapeutic conc. Decreased overall systemic exposure w/ other antiepileptics known to be enzyme inducers eg, carbamazepine, phenytoin, phenobarb.
MIMS Class
Anticonvulsants
ATC Classification
N03AX18 - lacosamide ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Vimpat FC tab 100 mg
Packing/Price
56's (P6,300/box)
Form
Vimpat FC tab 50 mg
Packing/Price
56's (P3,388/box)
Form
Vimpat Injection soln for infusion 10 mg/mL
Packing/Price
20 mL x 5 × 1's (P16,925/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in